Edge
StocktwitsEarnings

Official STOCKTWITS Representative

$BMRN Q2 '26 Earnings Results & Recap
• Reported GAAP EPS of $0.23 down -81.60% YoY
• Reported revenue of $989.71M up 19.91% YoY
• BioMarin Pharmaceutical Inc. raised its full-year 2026 total revenue guidance to a range of $3.875 billion to $3.925 billion, with VOXZOGO revenue expected to reach at least $1 billion in 2026.Price since post
Advertisement|Remove ads.